

Мycobiota Biotechnology Research LTD

Объем требуемых инвестиций: **\$ 2 500 тыс.**

Intended use of investment required:

R&D	25%
Working capital	50%
Marketing	15%
Current assets	10%

Company profile:

Date of establish - August 16, 2004

2. Stage of development - Start up.

3. Size and source of investment to date - \$ 150,000

4. Industry - Biotechnology

5. Target market - Agriculture, medicine

6. Sales in 2003 - None

7. Intellectual property rights - 2 patents and patent applications.

Owners:

Legal entities **60%**

Individuals (1) **40%**

Share of government property **0%**

Management and key personnel:

Kuchkin Kyril Vladimirovich - Director

Shein Jury Germanovich - Director of the Russian research branch «Research laboratory Mikobiota».

Panteleev Dmitry Jur'evich - Inventor, the supervisor of studies company Mycobiota Biotechnology Research and Russian research branch "Research laboratory Mikobiota".

Products characteristics:

1. A set of biopesticides on a basis entomopathogenic mushrooms (EPM) for struggle against agricultural and wood wreckers, blood-sicking insects and the pharmacological active substances using allocated from EPM biologically active substances. Offered preparations have extremely natural origin and do not comprise the synthesized chemical or biological components.

2. Therapeutic ways of oncological therapy. In a basis of the given direction the new theory carcinogenesis, put forward in 1985 the Soviet scientists Ageenko A.I. and Erhovym B.C lays. On the basis of the new approach to a problem of a tumoral progression the diagnostic and therapeutic techniques which have shown in experiments and in practice the high efficiency were developed some. Result of researches became creation resolved by Ministry of Health of the Russian Federation to application in territory of the Russian Federation of universal trouble-shooting test on tumoral growth (TURTEST) which by results of tests has shown the high sensitivity and specificity (75-85 %) a combination to simplicity of statement and accounts of results of the test. It was the proof of validity of the new concept carcinogenesis, underlying the test.

Continuing development of works of the company, it was possible to achieve (in experiments spent on laboratory mice) on tumoral culture a differentiation of tumoral cells down to formation of ferruterous structures by them with obvious secretory the function, similar those at normal dairy glandulae.

These and other results which have followed behind it of experiments have allowed to draw the important theoretical and practical conclusions in biology of tumoral growth and his regulation.

Now the company conducts researches on allocation of a complex of working substances, with the purpose of creation of preparations for the person and the proof of universality and - or a generality of the mechanism of self-recognition of own antigenes tumoral cells at their progression.

This direction of work of the company is not taken into account in the given offer and is given as informative.

Comparative analysis with existing alternatives:

Mycobiota Biotechnology Research	Monsanto (USA)
As against competitors, strongest of which is company Monsanto, offered production has extremely natural origin, in it there are no synthesized chemical and - or biological components. It will be agrees to precomputations cost of preparations 35 % above cost of the preparations made by competitors.	As against competitors, strongest of which is company Monsanto, offered production has extremely natural origin, in it there are no synthesized chemical and - or biological components.It will be agrees to precomputations cost of preparations 35 % above cost of the preparations made by competitors.

Despite of higher in comparison with let out preparations cost, company Mycobiota Biotechnology Research optimistically estimates market prospects of offered production.

Our optimism is based that

- all assumed to a conclusion to the market preparations have extremely natural origin and, as against the pesticides synthesized chemically, do not collect in plants and ground. Thus, in an organism of the person and an environment does not get any artificial chemical compounds.
 - offered products do not concern to a class of genetically modified biological objects that is unconditional plus for consumers. Because of changes in the nature protection legislation, taxes and installations of consumers the European demand for pesticides is reduced, and the market of biopesticides becomes - at least on the percentage parameters - the basic base for growth of demand. It agrees carried out(spent) by company Frost and Sullivan to research of the market of biopesticides, the revolution of this sector of the market will be increased annually by 11.7 % and by 2007 will make \$ 210 million Same tendency is observed not only in Europe, but also other countries of the world.
- All this allows the company to hope for commercial success and good market prospects.